Drs. Crawford and Hou provide an important clinical introduction to a novel class of hormonal agents that have been under development for several decades for the treatment of advanced and metastatic prostate cancer.
Marc B. Garnick, MD
Advertisement
Articles by Marc B. Garnick, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
I-DXd Earns FDA Priority Review in Extensive-Stage Small Cell Lung Cancer
2
FDA Grants Fast Track Designation to Daretabart for High-Risk Neuroblastoma
3
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer
4
Daraxonrasib Shows "Unprecedented" Survival in Pretreated Pancreatic Cancer
5